Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 28, 2025
FDA Issues Complete Response Letter for Etripamil for PSVT
GlobeNewswire
·
March 28, 2025
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. ( …
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
GlobeNewswire
·
March 28, 2025
FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancer Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC expected by mid-2025 SAN …
60 Degrees Pharmaceuticals Announces 2024 Annual Results
GlobeNewswire
·
March 28, 2025
FY 2024 net product revenues increased 140% to $607.6 thousand. FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to $222.8 thousand. WASHINGTON, March 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ( …
Winstrol Steroid: Benefits, Side Effects, Results & Buy Winstrol Pills Alternatives From CrazyBulk
GlobeNewswire
·
March 28, 2025
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- There exist numerous approaches to enhance muscle growth, a tantalizing prospect for many. However, achieving substantial muscle gains is far from instantaneous. Merely engaging in physical activities won't …
Ligandrol (LGD-4033) SARMs: Benefits, Results & Buy Ligandrol Pills Alternatives From CrazyBulk
GlobeNewswire
·
March 28, 2025
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- A significant portion of the populace leads lifestyles that compromise both cognitive and physical functionality. Prioritizing a healthy lifestyle is paramount for optimal brain and body performance, fostering a …
ProvaDent Reviews (Is It Safe And Legit?) Investigative Report On Ingredients, Side Effects, And Benefits!
GlobeNewswire
·
March 28, 2025
TALLMADGE, Ohio, March 28, 2025 (GLOBE NEWSWIRE) -- ProvaDent is precisely fabricated to support oral health by promoting a balanced oral microbiome. It works to encourage the growth of beneficial bacteria while reducing harmful ones. Maintaining this …
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
GlobeNewswire
·
March 28, 2025
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved …
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
GlobeNewswire
·
March 28, 2025
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first …
Communiqué de presse : Le Dupixent devient le tout premier biomédicament approuvé au Japon pour le traitement de la BPCO
GlobeNewswire
·
March 28, 2025
Le Dupixent devient le tout premier biomédicament approuvé au Japon pour le traitement de la BPCO Cette approbation fait suite à celle obtenue récemment dans l’Union européenne, en Chine et aux États-Unis et repose sur les résultats pivots de phase III …
Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint
GlobeNewswire
·
March 28, 2025
Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R…
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
GlobeNewswire
·
March 28, 2025
Châtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved DBV secures $125.5 …
DBV Technologies Annonce un Financement pouvant atteindre 306,9 millions de dollars (284,5 millions d’euros) permettant d’avancer le programme Viaskin® Peanut jusqu’au dépôt d'une Demande de Licence Biologique (BLA) et d’assurer la...
GlobeNewswire
·
March 28, 2025
Châtillon, France, le 28 mars (3h30 CET) 2025 DBV Technologies Annonce un Financement pouvant atteindre 306,9 millions de dollars (284,5 millions d’euros) permettant d’avancer le programme Viaskin® Peanut jusqu’au dépôt d'une Demande de Licence Biologique …